
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MTX-101
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : MetasTx
Deal Size : Undisclosed
Deal Type : Partnership
Details : The stability and efficacy of MTX-101 (IPA-3), are significantly superior in inhibiting prostate tumor growth and metastasis in various mouse models of prostate cancer and demonstrate broad applicability across solid tumor cancers.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 07, 2022
Lead Product(s) : MTX-101
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : MetasTx
Deal Size : Undisclosed
Deal Type : Partnership
